The format was 45 minutes of Q&A with CEO David Guyer (no prepared presentation), covering a lot of ground. There were no new revelations, but there was additional color on several aspects of the AMD market. This is definitely worth a listen for GENR investors.
Among the more notable points covered in the webcast was the degree to which practicing ophthalmologists may be favorably inclined toward intravitreal injections from a reimbursement perspective. Medicare reimburses each intravitreal injection at approximately $340, even though it requires only a few seconds of labor. Note that this $340 is over and above the reimbursement for whatever drug is being injected.
Since a Macugen patient can receive as many as nine injections per year, that comes to 9x$340, more than $3,000 of almost pure profit for the doctor per patient per year. No wonder there's a lot of support for Macugen in the ophthalmic community.
Market Data 
Markets 
AI
